[go: up one dir, main page]

DK3533796T3 - Aminopyrazolopyrimidinforbindelse anvendt som neutrof faktor tyrosinkinasereceptor inhibitor - Google Patents

Aminopyrazolopyrimidinforbindelse anvendt som neutrof faktor tyrosinkinasereceptor inhibitor Download PDF

Info

Publication number
DK3533796T3
DK3533796T3 DK17863410.1T DK17863410T DK3533796T3 DK 3533796 T3 DK3533796 T3 DK 3533796T3 DK 17863410 T DK17863410 T DK 17863410T DK 3533796 T3 DK3533796 T3 DK 3533796T3
Authority
DK
Denmark
Prior art keywords
neutrof
aminopyrazolopyrimidine
tyrosinkinase
factor
compound used
Prior art date
Application number
DK17863410.1T
Other languages
English (en)
Inventor
Li Zhu
Yuandong Hu
Wei Wu
Liguang Dai
Xiaowei Duan
Yanqing Yang
Yinghui Sun
Yongxin Han
Yong Peng
Fansheng Kong
Hong Luo
Zhaobai Zhong
Ling Yang
Hongjiang Xu
Meng Guo
Shanchun Wang
Original Assignee
Chia Tai Tianqing Pharmaceutical Group Co Ltd
Centaurus Biopharma Co Ltd
Lianyungang Runzhong Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chia Tai Tianqing Pharmaceutical Group Co Ltd, Centaurus Biopharma Co Ltd, Lianyungang Runzhong Pharmaceutical Co Ltd filed Critical Chia Tai Tianqing Pharmaceutical Group Co Ltd
Application granted granted Critical
Publication of DK3533796T3 publication Critical patent/DK3533796T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
DK17863410.1T 2016-10-28 2017-10-27 Aminopyrazolopyrimidinforbindelse anvendt som neutrof faktor tyrosinkinasereceptor inhibitor DK3533796T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201610970314 2016-10-28
CN201710044000 2017-01-21
PCT/CN2017/108100 WO2018077246A1 (zh) 2016-10-28 2017-10-27 用作神经营养因子酪氨酸激酶受体抑制剂的氨基吡唑并嘧啶化合物

Publications (1)

Publication Number Publication Date
DK3533796T3 true DK3533796T3 (da) 2021-11-08

Family

ID=62024344

Family Applications (1)

Application Number Title Priority Date Filing Date
DK17863410.1T DK3533796T3 (da) 2016-10-28 2017-10-27 Aminopyrazolopyrimidinforbindelse anvendt som neutrof faktor tyrosinkinasereceptor inhibitor

Country Status (16)

Country Link
US (1) US10829492B2 (da)
EP (1) EP3533796B1 (da)
JP (1) JP7046940B2 (da)
KR (1) KR102616249B1 (da)
CN (1) CN109890820B (da)
AU (1) AU2017348826B2 (da)
BR (1) BR112019008656A8 (da)
CA (1) CA3041942C (da)
DK (1) DK3533796T3 (da)
ES (1) ES2896943T3 (da)
HU (1) HUE057733T2 (da)
MX (1) MX380283B (da)
PL (1) PL3533796T3 (da)
PT (1) PT3533796T (da)
RU (1) RU2764523C2 (da)
WO (1) WO2018077246A1 (da)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110945000B (zh) * 2017-08-23 2021-09-03 正大天晴药业集团股份有限公司 含有氨基吡唑并嘧啶的大环化合物及其药物组合物和用途
CN108794370A (zh) * 2018-07-31 2018-11-13 上海弈柯莱生物医药科技有限公司 一种拉罗替尼中间体的制备方法
US20210395256A1 (en) * 2018-12-07 2021-12-23 Betta Pharmaceuticals Co., Ltd. Tyrosine kinase inhibitors, compositions and methods there of
US20220177477A1 (en) 2019-03-19 2022-06-09 Central China Normal University Pyrazolopyrimidine compound, pharmaceutical composition, and application therefor
CN112979654B (zh) * 2019-12-16 2024-03-19 赛诺哈勃药业(成都)有限公司 杂芳基稠环化合物、其制备方法及应用
TW202214635A (zh) * 2020-06-11 2022-04-16 大陸商貝達藥業股份有限公司 酪氨酸激酶抑制劑的鹽型、晶型、藥物組合物及其用途
CN111620881B (zh) * 2020-07-08 2023-03-31 浙江合聚生物医药有限公司 拉罗替尼衍生物及其制备方法和应用
CN113563343B (zh) * 2020-07-27 2022-05-24 杭州邦顺制药有限公司 取代的吡唑并[1,5-a]嘧啶化合物及其用途
CN112010860B (zh) * 2020-08-05 2023-03-10 南京纳丁菲医药科技有限公司 苄氧基吡唑并嘧啶化合物和药物组合物及其应用
CN114437075A (zh) * 2020-11-03 2022-05-06 上海瑶琪生物科技有限公司 用作ntrk激酶抑制剂的化合物及其应用
EP4335441A4 (en) * 2021-05-03 2024-10-16 JBKLAB Co., Ltd. PHARMACEUTICAL COMPOSITION FOR THE PREVENTION, Palliation OR TREATMENT OF CANCER WITH 2,6-DICHLORO-4-(4-(4-HYDROXYCYCLOHEXYLAMINO)-7H-PYRROLO[2,3-D!PYRIMIDIN-5-YL)PHENOL AS ACTIVE INGREDIENT
CN117751121A (zh) * 2021-07-30 2024-03-22 正大天晴药业集团股份有限公司 氨基吡唑并嘧啶化合物的晶体
CN117597129A (zh) * 2021-08-06 2024-02-23 正大天晴药业集团股份有限公司 氨基吡唑并嘧啶化合物在治疗trk激酶介导的肿瘤中的用途
CN117088800B (zh) * 2023-08-18 2024-05-28 龙曦宁(上海)医药科技有限公司 一种5-甲基吡咯烷-3-醇盐酸盐的制备方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10356579A1 (de) 2003-12-04 2005-07-07 Merck Patent Gmbh Aminderivate
JP5492194B2 (ja) 2008-05-13 2014-05-14 アイアールエム・リミテッド・ライアビリティ・カンパニー キナーゼ阻害剤としての縮合窒素含有ヘテロ環およびその組成物
WO2010003025A1 (en) 2008-07-01 2010-01-07 Genentech, Inc. Bicyclic heterocycles as mek kinase inhibitors
CA2738026C (en) 2008-09-22 2017-01-24 Array Biopharma Inc. Substituted imidazo[1,2b]pyridazine compounds as trk kinase inhibitors
EP2725028B1 (en) 2008-10-22 2016-05-25 Array Biopharma, Inc. Substituted pyrazolo[1,5-]pyrimidine compounds as intermediates in the synthesis of TRK kinase inhibitors
AR077468A1 (es) 2009-07-09 2011-08-31 Array Biopharma Inc Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa
WO2012034095A1 (en) 2010-09-09 2012-03-15 Irm Llc Compounds and compositions as trk inhibitors
KR20140014184A (ko) 2011-02-25 2014-02-05 아이알엠 엘엘씨 Trk 억제제로서의 화합물 및 조성물
US9096605B2 (en) 2011-08-24 2015-08-04 Glaxosmithkline Llc Pyrazolopyrimidine derivatives as PI3 kinase inhibitors
AU2012351748B2 (en) * 2011-12-12 2016-04-14 Dr. Reddy's Laboratories Ltd. Substituted pyrazolo[1,5-a] pyridine as tropomyosin receptor kinase (Trk) inhibitors
MX353336B (es) * 2013-02-19 2018-01-09 Ono Pharmaceutical Co Compuesto inhibidor de cinasa del receptor de tropomiosina (trk).
JP2016512816A (ja) * 2013-03-15 2016-05-09 バーテックス ファーマシューティカルズ インコーポレイテッドVertex Pharmaceuticals Incorporated Atrキナーゼの阻害剤として有用な化合物
CN104650092B (zh) * 2013-11-16 2017-11-10 广东东阳光药业有限公司 取代的杂芳基化合物及其组合物和用途
RU2720408C2 (ru) * 2013-12-06 2020-04-29 Вертекс Фармасьютикалз Инкорпорейтед Способ получения ингибиторов atr киназы (варианты)
AU2015365587B2 (en) * 2014-12-15 2020-07-23 Cmg Pharmaceutical Co., Ltd. Fused ring heteroaryl compounds and their use as TRK inhibitors

Also Published As

Publication number Publication date
JP2019537588A (ja) 2019-12-26
HUE057733T2 (hu) 2022-06-28
AU2017348826A1 (en) 2019-05-23
US10829492B2 (en) 2020-11-10
RU2764523C2 (ru) 2022-01-18
BR112019008656A2 (pt) 2019-07-09
MX2019004847A (es) 2019-08-29
RU2019114600A (ru) 2020-11-30
MX380283B (es) 2025-03-12
JP7046940B2 (ja) 2022-04-04
KR20190067913A (ko) 2019-06-17
CA3041942A1 (en) 2018-05-03
AU2017348826B2 (en) 2021-12-02
EP3533796A1 (en) 2019-09-04
WO2018077246A1 (zh) 2018-05-03
ES2896943T3 (es) 2022-02-28
CA3041942C (en) 2023-03-14
EP3533796A4 (en) 2020-06-03
CN109890820B (zh) 2020-11-03
CN109890820A (zh) 2019-06-14
PT3533796T (pt) 2021-11-18
RU2019114600A3 (da) 2021-02-20
BR112019008656A8 (pt) 2022-06-07
KR102616249B1 (ko) 2023-12-21
EP3533796B1 (en) 2021-09-29
PL3533796T3 (pl) 2022-01-17
US20190352306A1 (en) 2019-11-21

Similar Documents

Publication Publication Date Title
DK3533796T3 (da) Aminopyrazolopyrimidinforbindelse anvendt som neutrof faktor tyrosinkinasereceptor inhibitor
CY2024003I2 (el) Ενωσεις χρησιμες ως αναστολεις κινασης
DK3656769T3 (da) Aryl-phosphor-oxygen-forbindelse som egfr-kinase-inhibitor
DK3697785T3 (da) Imidazo-pyridine forbindelser som pad-inhibitorer
DK3442980T3 (da) Heterocykliske forbindelser som ret-kinase-hæmmere
DK3728252T3 (da) 4-azaindolforbindelser
EP3578560A4 (en) QUINAZOLINE COMPOUND
DK3436461T3 (da) Pyrrolotriazinforbindelser som tam-inhibitorer
DK3293186T3 (da) Pyrimidinoner som faktor xia-hæmmere
DK3371190T3 (da) Heterocykliske forbindelser som pi3k-gamma-inhibitorer
DK3303348T3 (da) Naphthyridinforbindelser som JAK-kinaseinhibitorer
DK3105218T3 (da) Cyclopropylaminer som lsd1-inhibitorer
DK3105226T3 (da) Cyclopropylaminer som lsd1-inhibitorer
PL3209656T3 (pl) Związki indolo-karboksyamidu użyteczne jako inhibitory kinazy
DK3294713T3 (da) Substituerede tetrahydroquinolinonforbindelser som ror-gamma-modulatorer
DK3762368T3 (da) Aminopyrazindiolforbindelser som pi3k-y-inhibitorer
DK3538528T3 (da) Pyrrolamider som alpha v-integrinhæmmere
DK3458460T3 (da) Imidazoler som histondemethylase-inhibitorer
DK3544981T3 (da) Benzodiazoliumforbindelser som enac-inhibitorer
DK4039675T3 (da) Phenyl-2-hydroxy-acetylamino-2-methyl-phenyl forbindelser
LT3464336T (lt) Junginiai
DK3638680T3 (da) Heteroaromatiske forbindelser som vanininhibitorer
DK3717488T3 (da) Substituerede furanopyrimidinforbindelser som pde1-inhibitorer
DK3548646T3 (da) Novel korrosionshæmmende pakke
DK3240767T3 (da) Mikroindkapslede nitrifikationshæmmersammensætninger